The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer

Expert Review of Anticancer Therapy

Volumn 12, Issue 4, 2012, Pages 469-480

  Kimple, Randall J ^a   Russo, Suzanne ^b   Monjazeb, Arta ^c   Blackstock, A William ^d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

biological markers; combined modality therapy; molecular targets; neoadjuvant; pancreatic adenocarcinoma; radiotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PLACEBO; SORAFENIB; THYMIDYLATE SYNTHASE;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; DRUG TOLERABILITY; HUMAN; INTERMETHOD COMPARISON; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS SURGERY; PERSONALIZED MEDICINE; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; HUMANS; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 84859795721     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.18     Document Type: Review

References (100)

1. American Cancer Society. Selected cancers. In: Cancer Facts and Figures 2011. National Home Office: American Cancer Society Inc., GA, USA, 10-19 (2011).
2. SEER Cancer Statistics Review, 1975-2008. Howlader N, Noone A, Krapcho M et al. (Eds). National Cancer Institute, MD, USA (2010).
3. Chang DK, Johns AL, Merrett ND et al. Margin clearance and outcome in resected pancreatic cancer. J. Clin. Oncol. 27(17), 2855-2862 (2009).
4. Farnell MB, Pearson RK, Sarr MG et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 138(4), 618-628; discussion 628-630 (2005).
5. Riall TS, Cameron JL, Lillemoe KD et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma - Part 3: Update on 5-year survival. J. Gastrointest. Surg. 9(9), 1191-1204; discussion 1204-1196 (2005).
6. Pedrazzoli S, DiCarlo V, Dionigi R et al.Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: A multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann. Surg. 228(4), 508-517 (1998). (Pubitemid 30194394)
7. Tepper J, Nardi G, Sutt H. Carcinoma of the pancreas: Review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer 37(3), 1519-1524 (1976).
8. Iacobuzio-Donahue CA, Fu B, Yachida S et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J. Clin. Oncol. 27(11), 1806-1813 (2009).
9. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J. Surg. 21(2), 195-200 (1997). (Pubitemid 27053441)
10. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J. Gastrointest. Surg. 10(4), 511-518 (2006). (Pubitemid 43619152)
11. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 72(7), 2118-2123 (1993). (Pubitemid 23280135)
12. Westerdahl J, Andren-Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer - Local or hepatic? Hepatogastroenterology 40(4), 384-387 (1993). (Pubitemid 23258561)
13. Whittington R, Bryer MP, Haller DG, Solin LJ, Rosato EF. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int. J. Radiat. Oncol. Biol. Phys. 21(5), 1137-1143 (1991).
14. Griffin JF, Smalley SR, Jewell W et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 66(1), 56-61 (1990). (Pubitemid 20197085)
15. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 59(12), 2006-2010 (1987).
16. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg. 120(8), 899-903 (1985). (Pubitemid 15040883)
17. Klinkenbijl JH, Jeekel J, Sahmoud T et al.Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann. Surg. 230(6), 776-782; discussion 782-774 (1999).
18. Smeenk HG, van Eijck CH, Hop WC et al. Long-Term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: Long-Term results of EORTC trial 40891. Ann. Surg. 246(5), 734-740 (2007). (Pubitemid 350035648)
19. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350(12), 1200-1210 (2004). (Pubitemid 38339364)
20. Neoptolemos JP, Dunn JA, Stocken DD et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. Lancet 358(9293), 1576-1585 (2001). (Pubitemid 33101907)
21. Abrams RA, Winter KA, Regine WF et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704-A Phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int. J. Radiat. Oncol. Biol. Phys. 82(2), 809-816 (2011).
22. Neoptolemos JP, Stocken DD, Tudur Smith C et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: Composite data from the ESPAC-1 and -3(v1) trials. Br. J. Cancer 100(2), 246-250 (2009).
23. Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA 304(10), 1073-1081 (2010).
24. Regine WF, Winter KA, Abrams RA et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 299(9), 1019-1026 (2008). (Pubitemid 351347058)
25. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297(3), 267-277 (2007). (Pubitemid 46143304)
26. Neuhaus P, Riess H, Post S et al. CONKO-001: Final results of the randomized, prospective, multicenter Phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J. Clin. Oncol. 26(Suppl. 20) LBA4504 (2008).
27. Hsu CC, Herman JM, Corsini MM et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: The Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann. Surg. Oncol. 17(4), 981-990 (2010).
28. Van Laethem JL, Hammel P, Mornex F et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: A randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II study. J. Clin. Oncol. 28(29), 4450-4456 (2010).
29. Berlin J, Catalano P, Feng Y, Lowy A, Blackstock A, Philip P. ECOG 2204: An intergroup randomized Phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely resected pancreatic adenocarcinoma (PC). J. Clin. Oncol. 28(Suppl. 15), 4034 (2010).
30. Evans DB, Rich TA, Byrd DR et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch. Surg. 127(11), 1335-1339 (1992).
31. Evans DB, Varadhachary GR, Crane CH et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J. Clin. Oncol. 26(21), 3496-3502 (2008).
32. Varadhachary GR, Wolff RA, Crane CH et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J. Clin. Oncol. 26(21), 3487-3495 (2008).
33. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-Analysis of response and resection percentages. PLoS Med. 7(4), e1000267 (2010).
34. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53(4), 549-554 (1988).
35. Hirai H, Okabe T, Anraku Y, Fujisawa M, Urabe A, Takaku F. Activation of the c-K-ras oncogene in a human pancreas carcinoma. Biochem. Biophys. Res. Commun. 127(1), 168-174 (1985). (Pubitemid 15146946)
36. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(15), 1960-1966 (2007). (Pubitemid 46972777)
37. Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat. Rev. 35(3), 262-271 (2009).
38. Kimple R, Vaseva A, Cox A et al. Radiosensitization of pancreatic cancer cells via Akt inhibition. Clin. Cancer Res. 16(3), 912-923 (2010).
39. Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin. Cancer Res. 14(16), 5142-5149 (2008).
40. Brunner TB, Geiger M, Grabenbauer GG et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J. Clin. Oncol. 26(16), 2699-2706 (2008).
41. Bloomston M, Marsh C, Walker J et al. Phase I trial of gene-mediated cytotoxic immunotherapy in combination with chemoradiation for locally advanced pancreatic cancer. J. Clin. Oncol. 29(4), 195 (2011).
42. Lutz E, Yeo CJ, Lillemoe KD et al. A lethally irradiated allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann. Surg. 253(2), 328-335 (2011).
43. Pawlik TM, Gleisner AL, Cameron JL et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 141(5), 610-618 (2007). (Pubitemid 46616937)
44. Riediger H, Keck T, Wellner U et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J. Gastrointest. Surg. 13(7), 1337-1344 (2009).
45. Slidell MB, Chang DC, Cameron JL et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: A large, population-based analysis. Ann. Surg. Oncol. 15(1), 165-174 (2008).
46. Dong M, Zhou JP, Zhang H, Guo KJ, Tian YL, Dong YT. Clinicopathological significance of Bcl-2 and Bax protein expression in human pancreatic cancer. World J. Gastroenterol. 11(18), 2744-2747 (2005). (Pubitemid 40704240)
47. Magistrelli P, Coppola R, Tonini G et al. Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma. J. Cell. Biochem. 97(1), 98-108 (2006). (Pubitemid 43050182)
48. Nio Y, Iguchi C, Yamasawa K et al. Apoptosis and expression of Bcl-2 and Bax proteins in invasive ductal carcinoma of the pancreas. Pancreas 22(3), 230-239 (2001). (Pubitemid 32242487)
49. Kami K, Doi R, Koizumi M et al. Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery 136(2), 443-448 (2004). (Pubitemid 39037686)
50. Tonini G, Vincenzi B, Santini D et al. Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. Br. J. Cancer 92(12), 2225-2232 (2005). (Pubitemid 40966261)
51. Oida Y, Yamazaki H, Tobita K et al. Increased S100A4 expression combined with decreased E-cadherin expression predicts a poor outcome of patients with pancreatic cancer. Oncol. Rep. 16(3), 457-463 (2006).
52. Shimamura T, Sakamoto M, Ino Y et al. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: Relationship to E-cadherin expression. J. Clin. Oncol. 21(4), 659-667 (2003). (Pubitemid 46621900)
53. Matsubayashi H, Infante JR, Winter J et al. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol. Ther. 6(10), 1569-1575 (2007). (Pubitemid 351590328)
54. Juuti A, Louhimo J, Nordling S, Ristimaki A, Haglund C. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J. Clin. Pathol. 59(4), 382-386 (2006).
55. Chang D, Colvin E, Scarlett C, Pajic M, Pinese M, Gill A. A molecular prognostic nomogram for resectable pancreatic cancer. J. Clin. Oncol. 29(4), 154 (2011).
56. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390(6659), 465-471 (1997). (Pubitemid 28013118)
57. Crane CH, Varadhachary GR, Yordy JS et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(DPC4) immunostaining with pattern of disease progression. J. Clin. Oncol. 29(22), 3037-3043 (2011).
58. Palmer DH, Stocken DD, Hewitt H et al. A randomized Phase II trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatin. Ann. Surg. Oncol. 14(7), 2088-2096 (2007). (Pubitemid 46988260)
59. Talamonti MS, Small W Jr, Mulcahy MF et al. A multi-institutional Phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann. Surg. Oncol. 13(2), 150-158 (2006). (Pubitemid 43157408)
60. Le Scodan R, Mornex F, Girard N et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: Feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann. Oncol. 20(8), 1387-1396 (2009).
61. Moutardier V, Turrini O, Huiart L et al. A reappraisal of preoperative chemoradiation for localized pancreatic head ductal adenocarcinoma in a 5-year single-institution experience. J. Gastrointest. Surg. 8(4), 502-510 (2004). (Pubitemid 38561216)
62. White RR, Tyler DS. Neoadjuvant therapy for pancreatic cancer: The Duke experience. Surg. Oncol. Clin. N. Am. 13(4), 675-684, ix-x (2004). (Pubitemid 39209347)
63. Pisters PW, Abbruzzese JL, Janjan NA et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J. Clin. Oncol. 16(12), 3843-3850 (1998). (Pubitemid 29001537)
64. Stokes JB, Nolan NJ, Stelow EB et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann. Surg. Oncol. 18(3), 619-627 (2011).
65. Landry J, Catalano PJ, Staley C et al. Randomized Phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J. Surg. Oncol. 101(7), 587-592 (2010).
66. Small W Jr, Berlin J, Freedman GM et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: A multicenter Phase II trial. J. Clin. Oncol. 26(6), 942-947 (2008). (Pubitemid 351398088)
67. Golcher H, Brunner T, Grabenbauer G et al. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Eur. J. Surg. Oncol. 34(7), 756-764 (2008).
68. Allendorf JD, Lauerman M, Bill A et al. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: Feasibility, efficacy, and survival. J. Gastrointest. Surg. 12(1), 91-100 (2008).
69. Massucco P, Capussotti L, Magnino A et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: Analysis of perioperative outcome and survival. Ann. Surg. Oncol. 13(9), 1201-1208 (2006). (Pubitemid 44440421)
70. Pipas JM, Barth RJ Jr, Zaki B et al. Docetaxel/gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann. Surg. Oncol. 12(12), 995-1004 (2005). (Pubitemid 41660675)
71. Joensuu TK, Kiviluoto T, Karkkainen P et al. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 60(2), 444-452 (2004). (Pubitemid 39233463)
72. Ammori JB, Colletti LM, Zalupski MM et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J. Gastrointest. Surg. 7(6), 766-772 (2003). (Pubitemid 37103131)
73. Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 89(2), 314-327 (2000). (Pubitemid 30489879)
74. Kamthan AG, Morris JC, Dalton J et al. Combined modality therapy for stage II and stage III pancreatic carcinoma. J. Clin. Oncol. 15(8), 2920-2927 (1997). (Pubitemid 27330020)
75. Philip P, Benedetti J, Fenoglio-Preiser C et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J. Clin. Oncol. 25(18S), 199s (2007).
76. Brell JM, Matin K, Evans T et al. Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. Oncology 76(4), 270-274 (2009).
77. Van Cutsem E, Van De Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 22(8), 1430-1438 (2004). (Pubitemid 41103625)
78. Safran H, Iannitti D, Ramanathan R et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest. 22(5), 706-712 (2004). (Pubitemid 40064730)
79. Safran H, Miner T, Resnick M et al. Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: A Phase I study for advanced pancreaticobiliary cancer. Am. J. Clin. Oncol. 31(2), 140-144 (2008). (Pubitemid 351519165)
80. Safran H, Steinhoff M, Mangray S et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am. J. Clin. Oncol. 24(5), 496-499 (2001). (Pubitemid 32959109)
81. Dugan MC, Dergham ST, Kucway R et al. HER-2/neu expression in pancreatic adenocarcinoma: Relation to tumor differentiation and survival. Pancreas 14(3), 229-236 (1997). (Pubitemid 27149046)
82. Kindler HL, Niedzwiecki D, Hollis D et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28(22), 3617-3622 (2010).
83. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial. J. Clin. Oncol. 19(15), 3447-3455 (2001). (Pubitemid 32730080)
84. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first-line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 87(2), 161-167 (2002).
85. Moore MJ, Hamm J, Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21(17), 3296-3302 (2003). (Pubitemid 46606263)
86. Dragovich T, Burris H 3rd, Loehrer P et al. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: Results of a Phase II trial. Am. J. Clin. Oncol. 31(2), 157-162 (2008). (Pubitemid 351519167)
87. El-Rayes BF, Zalupski MM, Shields AF et al. A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest. New Drugs 23(6), 583-590 (2005). (Pubitemid 43162479)
88. Ferrari V, Valcamonico F, Amoroso V et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: A Phase II trial. Cancer Chemother. Pharmacol. 57(2), 185-190 (2006). (Pubitemid 41779837)
89. Wolpin BM, Hezel AF, Abrams T et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol. 27(2), 193-198 (2009).
90. Andrianifahanana M, Moniaux N, Schmied BM et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: A potential role of MUC4 as a tumor marker of diagnostic significance. Clin. Cancer Res. 7(12), 4033-4040 (2001). (Pubitemid 34044624)
91. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Down-regulation of Notch-1 inhibits invasion by inactivation of nuclear factor-kappa-B, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 66(5), 2778-2784 (2006).
92. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol. Cancer Ther. 5(3), 483-493 (2006).
93. Uwagawa T, Chiao PJ, Gocho T, Hirohara S, Misawa T, Yanaga K. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation. Anticancer Res. 29(8), 3173-3178 (2009).
94. Uwagawa T, Misawa T, Sakamoto T et al. A Phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Ann. Oncol. 20(2), 239-243 (2009).
95. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 65(15), 6934-6942 (2005). (Pubitemid 41060733)
96. Wang Z, Zhang Y, Banerjee S, Li Y, Sarkar FH. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106(11), 2503-2513 (2006). (Pubitemid 43787677)
97. Buchler P, Gazdhar A, Schubert M et al. The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann. Surg. 242(6), 791-800, discussion 800-791 (2005).
98. Fahy BN, Schlieman M, Virudachalam S, Bold RJ. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br. J. Cancer 89(2), 391-397 (2003). (Pubitemid 36976331)
99. Chadha KS, Khoury T, Yu J et al. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann. Surg. Oncol. 13(7), 933-939 (2006).
100. Cheng JQ, Ruggeri B, Klein WM et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl Acad. Sci. USA 93(8), 3636-3641 (1996). (Pubitemid 26127592)